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Abstract
Background: Integration of human immunodeficiency virus type 1 (HIV-1) into the host genome causes global
disruption of the chromatin environment. The abundance level of various chromatin-modifying enzymes produces
these alterations and affects both the provirus and cellular gene expression. Here, we investigated potential
changes in enzyme expression and global DNA methylation in chronically infected individuals with HIV-1 and
compared these changes with non-HIV infected individuals. We also evaluated the effect of viral replication and
degree of disease progression over these changes.
Results: Individuals with HIV-1 had a significant surge in the expression of DNA and histone methyltransferases
(DNMT3A and DNMT3B, SETDB1, SUV39H1) compared with non-infected individuals, with the exception of PRMT6,
which was downregulated. Some histone deacetylases (HDAC2 and HDAC3) were also upregulated in patients with
HIV. Among individuals with HIV-1 with various degrees of progression and HIV control, the group of treated
patients with undetectable viremia showed greater differences with the other two groups (untreated HIV-1
controllers and non-controllers). These latter two groups exhibited a similar behavior between them. Of interest, the
overexpression of genes that associate with viral protein Tat (such as SETDB1 along with DNMT3A and HDAC1, and
SIRT-1) was more prevalent in treated patients. We also observed elevated levels of global DNA methylation in
individuals with HIV-1 in an inverse correlation with the CD4/CD8 ratio.
Conclusions: The current study shows an increase in chromatin-modifying enzymes and remodelers and in global
DNA methylation in patients with chronic HIV-1 infection, modulated by various levels of viral control and progression.
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Background
Chromatin is a highly dynamic structure that, during hu-
man immunodeficiency virus (HIV) infection, is altered by
the viral integration into the host genome and the host
immune response that follows. This virus-host interaction
creates an epigenetic environment with a two-way effect.
On the one hand, the virus can be modified by chromatin-
related events either to increase its replication efficiency
or to become transcriptionally inert [1, 2]. On the other
hand, T lymphocyte gene expression is modulated to cre-
ate a cellular environment that favors the establishment of
infection, promotes viral replication, and facilitates viral
persistence. These chromatin changes are directed by a
wide battery of chromatin-modifying enzymes and DNA-
associated proteins.
Many phases of the HIV cycle—integration, maintenance
of the provirus, and transcriptional activation or silencin-
g—are directly influenced by local chromatin reorganization
and abundance of related enzymes. In newly infected cells,
the virus is led by chromatin-interacting proteins to targeted
DNA sites, especially CpG islands and promoters [3, 4].
Upon integration, the balance between several chromatin-
modifying factors creates a more or less permissive environ-
ment for viral transcription [5]. The proviral long terminal
repeat (LTR) promoter is complexed with two nucleosomes
(nuc-0 and nuc-1) that can modify their conformation
through binding of multimolecular complexes of histone
acetyltransferases (HATs), histone deacetyltransferases
(HDACs), and other enzymes. The deposition of nuc-1 is
key to the regulation of HIV gene expression. For example,
HDAC1, HDAC2, and HDAC3 are main factors that medi-
ate the deacetylation of nuc-1 and compact chromatin [6].
Other proteins that interact with nuc-1 and modulate HIV-
1 replication through chromatin reorganization are histone
methyltransferases (HMTs) such as SUV39H1 [7], DNA
methyltransferases (DNMTs) such as DNMT1 [5], or
methyl-CpG binding domain protein 2 (MBD2) [8]. Viral
proteins are highly involved in this complex interplay of
chromatin rearrangements. Among them, the viral protein
Tat is crucial for maintaining the equilibrium of various
chromatin-modifying factors for the benefit of viral persist-
ence. Following its synthesis, Tat favors the recruitment of
various HATs toward a more permissive chromatin state
and active viral replication [9]. Tat itself can be acetylated
by some HATs (CBP/p300 and GCN5) to facilitate its inter-
action with critical cellular proteins and activate viral RNA
transcription; without this modification, viral expression
would be minimal [10]. At the end of the viral transcription
process, Tat is deacetylated by Sirtuin 1 (SIRT1, a class III
HDAC) to allow for its recycling [11]. At the same time,
however, Tat appears to be a potent inhibitor of SIRT1 in
vitro [12]. This second effect of Tat over SIRT1 results in T
cell hyperactivation. Although a paradox, this process sug-
gests a complex interaction of Tat with host epigenetic
mechanisms, with various effects dependent on Tat concen-
tration and possibly disease stage.
Methyltransferases such as SET domain bifurcated 1
(SETDB1) and protein arginine methyltransferase 6
(PRMT6) also associate with Tat, creating additional levels
of viral transcriptional regulation. SETDB1 methylates Tat
at lysine 50 and 51 residues, which might initiate transcrip-
tional repression machinery through chromatin remodeling
[13], whereas methylation of Tat at lysine 52 and 53 residues
by PRMT6 decreases Tat binding to TAR and results in a
reduction of HIV transcription [14]. PRMT6 has been sug-
gested to be an HIV restriction factor used by the host.
Methyltransferases are also responsible for modifications of
DNA methylation. In this regard, the expression of DNA
methyltransferases appears to be altered by HIV infection.
DNMT1 expression has been reported to increase with
HIV-1 infection in vitro and to correlate with gene
methylation [15]. Likewise, methyltransferases can also
modify proviral DNA. In vitro studies have shown that
hypermethylation of the viral LTR promoter silences the
virus and helps establish a viral reservoir [8]. However, this
effect has been difficult to determine in vivo, because hypo-
methylated viral genomes appear to predominate in primary
blood cells from patients with HIV [16, 17]; thus, further ex-
ploration is required to quantify its contribution to latency
and reservoirs.
On the other hand, chromatin reorganization drives the
plasticity of immune cell populations in response to stimuli.
Differentiation of T cell subsets toward helper or regulatory
lineages is regulated by DNA methylation events, histones,
and other chromatin-modifying enzymes [18]. Key genes
such as IFNg, FOXP3, IL17, IL-2, and PD-1, among many
others, are modified by several epigenetic mechanisms. In
this regard, HIV-1 infection causes important epigenetic
changes in the T cell population that result in abnormal ex-
pression of proinflammatory cytokines and other immune-
related genes. This expression eventually leads to a persist-
ent deregulation of the immune system that is linked to
AIDS progression. DNA methylation changes caused by
HIV infection have been reported in many of these genes
(IFNg, IL-1, PD-1), and these changes are responsible for
the broad dysfunction of these cells [19–21].
Despite recognition of the participation of epigenetic
mechanisms in HIV-1 infection, there is a paucity of
data on the effects of HIV replication levels and the dur-
ation of disease on the epigenetic profiles of CD4+ T
cells in infected patients. A few in vitro studies mimick-
ing the acute infection in primary PBMCs and CD4+ T
cells have observed changes in expression of chromatin-
modifying enzymes [22, 23]; however, there are no data
on patients with long-term chronic infection.
In this context, the present study aimed to evaluate
the expression profiles of chromatin-modifying enzymes
in vivo in patients with chronic HIV-1. We also assessed
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how these factors behaved in various stages of disease by
analyzing patients with various phenotypes of viral con-
trol and degrees of disease progression.
Methods
Study population
A total of 129 individuals were included in the study. Sam-
ples from 43 individuals who were HIV-seropositive with
various degrees of disease progression and viral control
were kindly provided by the HIV BioBank integrated in the
Spanish AIDS Research Network [24]; the other 51 individ-
uals who were HIV-seropositive were recruited at Hospital
Carlos III in Madrid. Thirty-five HIV-seronegative individ-
uals were also enrolled for the study. Group assignment
within the HIV-seropositive individuals was based on their
degree of viral control and disease progression. The result-
ing groups for the final analysis were as follows: 26 chronic
progressors treated with cART who presented with un-
detectable plasmatic viral load for more than a year (here-
after, “cART recipients”); 32 untreated chronic viremic
patients with plasma viral loads above 10,000 copies/mL
(hereafter, “noncontrollers”); and 36 patients who controlled
viremia without treatment (hereafter, “HIV controllers”).
Within this latter group, 14 were long-term nonprogressors
(LTNPs: untreated patients, with more than 10 years of in-
fection and stable CD4+ T cell count above 500 cells/μL
and low levels of viremia) and 22 were elite controllers (EC:
untreated patients with undetectable viral load). The pa-
tients’ characteristics are described in detail in Table 1.
All participating individuals provided their informed
written consent, and the protocols were approved by the
institutional ethics committees. The clinical and epi-
demiological data provided for patients from the HIV Bio-
Bank were included in the adult cohort of the Spanish
AIDS Research Network (CoRIS), launched in 2004 [25].
Sample processing and nucleic acid extraction
Peripheral blood mononuclear cells were obtained from
each patient. Subsequently, CD4+ T cells were isolated
using the Dynabeads CD4 positive Isolation Kit from Life
Technologies, following the manufacturer’s instructions.
The purity of the cell fraction was > 98%, as determined by
flow cytometry (BD FACSCalibur). Finally, the extraction of
RNA and DNA from the CD4+ cells was performed using
the AllPrep DNA/RNA/Protein MiniKit (Qiagen). The ob-
tained RNA and DNA were quantified by spectrophotom-
etry using a NanoDrop, purity was also assessed by
spectrophotometry, and quality of nucleic acids was ana-
lyzed by electrophoresis. The RNA and DNA were con-
served at − 80 °C until their further use.
Quantification of mRNA by real-time PCR
Isolated mRNAs were reverse transcribed with the AMV-
RT Access RT-PCR System, (Promega Biotech), using ran-
dom primers (Biotools B&M Labs, Madrid, Spain) under
the following conditions: 95 °C for 5 min before adding the
AMV-RT enzyme, followed by incubation at 25 °C for
10 min, 40 °C for 30 min, 48 °C for 30 min, and a final in-
activation step of 80 °C for 2 min. Five separate reverse
transcription reactions were performed for each patients’
mRNAs, and the resulting cDNAs were pooled for qPCR
analysis. The obtained cDNA was amplified by quantitative
polymerase chain reaction using TaqMan® technology from
Life Technologies. The relative quantification of the genes
of interest was performed using TaqMan Array Gene Signa-
ture 96-well custom plates, structured as follows: 6 sets of
one manufacturing control (18 s), 2 endogenous controls
(GAPDH, B2M), and 12 gene expression assays (SETDB1,
DNMT3a, DNMT3b, HDAC1, HDAC2, HDAC3, HDAC6,
MBD2, HAT1, SUV39H1, PRMT6, SIRT1). One set was
occupied in all assays by the same reference sample, which
Table 1 Characteristics of the study participants, by group
HIV-positive HIV-negative p value
Noncontroller (without cART)
(n = 32)
cART recipient
(n = 26)
HIV-controller (without cART)
(n = 36)
(n = 35)
Age (years)a 35 (25.25–40) 49.5 (40.75–53.75) 44 (39.5–48.5) 49 (41–53) 0.022b
Sex (%)
Men 75 77 68 64 0.399b
Women 25 23 32 36
T cell count, cells/μLa
CD4+ 554 (478–713.5) 570 (435–760) 680 (574–1132) – 0.002
CD8+ 865 (736–1148) 694 (433–910) 1031 (622–1470) – 0.016
Viral loada
HIV-1 RNA copies/mL
26,956 (1512.75–54,579.50) < 20 28.5 (< 20–446.75) – < 0.001
Duration after diagnosis (years)a 0.16 (0.08–1) 12 (4.75–16) 14 (7.5–19) – < 0.001
cART combination antiretroviral therapy, NA not applicable, NS not significant
aData are median (interquartile range, IQR)
bData denote results of comparisons between HIV-positive vs. HIV-negative
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allow us to normalize intra- and inter-assays. The DNMT1
gene expression was analyzed using the TaqMan Gene Ex-
pression assay by Life Technologies in an individual format
using the same endogenous controls. All the samples were
run in duplicate. The assays were performed using an ABI
7500 System, following the manufacturer’s instructions.
Relative levels of gene expression were calculated using the
ΔΔCt method as previously described [26].
Protein extraction and Western blot analysis
Cells pellets were lysed on ice using the following extrac-
tion buffer: 50 mM Tris HCl pH = 7,5; 150 nM NaCl;
0,5%SDS; 30 mM PPi; NaF 0,5 M; and 100 μM Na3VO4
20 mM. A protease inhibitors cocktail (Calbiochem) was
added before extraction. Cell lysates were separated by
10% SDS-PAGE gel (Mini-PROTEAN TGX gels) and
transferred to nitrocellulose membrane (Amersham Pro-
tran 0,2 μm, GE Healthcare Life Science).Western blotting
was performed using primary antibodies anti DNMT1
(monoclonal antibody DNMT1 clone 60B1220.1, Epigen-
tek, Inc) and DNMT3a (anti-Dnmt3a ab4897, Abcam)
and anti ACTB (Actin C-11 sc1615, Santa Cruz Bitotech-
nology, Inc.) at dilutions 1:1000, 1:1000, and 1:750, re-
spectively. Secondary antibodies conjugated with HRP
were used at a dilution of 1:2000, and the reaction was re-
vealed using Amersham ECL Prime Western Blotting De-
tection Reagent by GE Healthcare Life Sciences, according
to the manufacturer’s instructions.
Due to sample limitation, only 27 individuals could be
analyzed: 8 HIV-seronegative and 19 HIV-seropositive
individuals (3 non-controllers, 10 cART recipients, and
6 HIV-controllers).
Global DNA methylation analysis
The amount of CpG 5′-methylcytosines in DNA was
measured in 100 ng of genomic DNA with the Methyl-
Flash Methylated DNA Quantification kit (Epigentek),
following the manufacturer’s instructions. Positive and
negative DNA methylation controls were included in the
kit. A standard curve was prepared in duplicate with the
positive control provided. All DNA samples were mea-
sured in duplicate.
Data analysis
To compare gene expression among the study groups,
nonparametric Mann-Whitney U and Kruskal-Wallis
tests were used when appropriate. For the correlation
analyses, we performed the Spearman rank correlation
test. Student’s t test was used to assess between-group
differences in DNA methylation. The association be-
tween the categorical variables was evaluated using the
Chi-squared test. A p value cutoff of 0.05 was used for
significance. The statistical analysis was performed using
SPSS software 15.0 (SPSS Inc., Chicago, Illinois, USA).
Results
First, we compared the expression of genes involved in
chromatin modification and other epigenetic mechanisms
on the CD4+ T cells of patients with HIV versus non-HIV
infected individuals. Results showed relevant differences
between both groups in almost all the analyzed genes
(Fig. 1). In detail, among the analyzed histone methyl-
transferases (HMTs: SETDB1, SUV39H1, and PRMT6)
shown in Fig. 1a, the expression of histone-lysine N-
methyltransferase SETDB1 was approximately four times
higher in patients with HIV (median = 2.01 vs. 0.52, p
< .001). The expression of PRMT6, however, was down-
regulated (three times lower) in individuals who were
HIV-positive (median = 0.44 vs. 1.38, p = .005). As for the
class I, II, and III histone deacetylases (HDAC1, HDAC2,
HDAC3, HDAC6, and SIRT1), all showed differences in
expression except HDAC1 (Fig. 1b). The highest differ-
ence was observed for HDAC2, with over sixfold upregu-
lation in patients with HIV-1 (median = 1.02 vs. 0.15, p
< .001). The three genes encoding for DNA methyltrans-
ferases (DNMT1, DNMT3A, and DNMT3B) were also
upregulated in HIV-infected individuals (Fig. 1c, d), with
the highest difference observed in DNMT3B (over sixfold
higher, median = 2.15 vs. 0.41, p < 0.001) (Fig. 1d). The
methyl-CpG binding protein MBD2 was also found to be
twofold higher in patients with HIV-1 (median = 1.28 vs.
0.64, p < 0.001) (Fig. 1c). Finally, histone acetyltransferase
1 (HAT1) also showed upregulation in patients with HIV-
1 (Fig. 1e). In a multivariate linear regression analysis,
none of these results was significantly confounded by age
or gender. Only HIV infection independently associated
with changes in gene expression.
We then compared gene expression within the various
groups of individuals with HIV-1, classified according to
their progression status, treatment, and viral control.
The group of combination antiretroviral therapy (cART)
recipients showed an overall surge in expression com-
pared with the noncontrollers’ group. We note the ele-
vated expression seen in DNMT3A and DNMTB in
cART recipients who control viral replication. All the
genes with significant differences between these two
groups are shown in detail in Table 2. On the other
hand, the HIV controllers behaved highly similar to non-
controllers with no differences in median values for any
analyzed gene, except for the expression of DNA meth-
yltransferases, which were slightly increased, although
not reaching significance due to wide dispersion of
values. Finally, we analyzed associations between genes
and observed a positive correlation of expression among
SETDB1, HDAC1, and DNMT3A (Fig. 2a). It is in the
group of cART recipients that these three genes showed
the greatest differences (Fig. 2b). The cART recipients
also showed the highest frequency of increased expres-
sion in these three genes simultaneously (Table 3).
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Western blot analysis showed slightly increased levels of
DNMT3a and DNMT1 expression in HIV-positive indi-
viduals compared to non-HIV infected, but due to small
sample size, differences were not significant. The median
values [IQR] for DNMT3a in HIV+ vs. HIV− were as fol-
lows: 0.215 [0.162–0.263] vs. 0.178 [0.111–0.214] p value
= 0.119 (Fig. 3b) and for DNMT1 1.390 [0.640–1.620] vs.
0.860 [0.35–1.52], p value = 0.260 (Fig. 3c).
The analysis of global 5′-methylcytosine in the genomic
DNA of CD4+ T cells showed a higher percentage of
methylation in the individuals with HIV-1 compared with
non-HIV infected individuals (Fig. 4a). Irrespective of HIV
status, the global DNA methylation was lower in older indi-
viduals (Spearman correlation coefficient rho = − 0.238, p =
0.015) and no effect of gender was observed. Within the
HIV-1 infected patients, the noncontroller and HIV-
controller groups showed a negative correlation between
DNA methylation and CD4+/CD8+ T cell ratio (Fig. 4b),
a b
c d e
Fig. 1 Chromatin-modifying enzyme expression profiling in individuals with chronic immunodeficiency virus type 1 infection-matched HIV-negative
controls. a Histone methyltransferases (HMTs); (b) histone deacetylases (HDACs) Class I, II, and III; (c) DNA methyltransferases 1 and 3a and methyl
binding protein; (d) DNA methyltransferase 3b; and (e) histone acetyltransferase 1. Y-exe values represent relative levels of mRNA obtained by the ΔΔCt
method. Horizontal bars indicate median values, boxes indicate interquartile range (IQR), and p values for each gene are indicated
Table 2 Differences in gene expression between cART
recipients and noncontrollers
Gene Median of gene expression (mRNA) Fold up (cART-
recipients vs.
noncontrollers)
p value
cART recipients Noncontrollers
SETDB1 2.69 1.26 + 2.15 0.033
PRMT6 0.56 0.23 + 2.43 0.006
SUV39H1 1.87 0.61 + 3.07 0.001
DNMT3a 2.01 0.42 + 4.79 < 0.001
DNMT3b 4.09 0.72 + 5.68 0.013
MBD2 1.79 0.74 + 2.42 < 0.001
HDAC1 1.74 0.74 + 2.35 0.002
HDAC2 1.46 0.52 + 2.80 0.003
SIRT1 1.08 0.69 + 1.56 0.001
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whereas this increase in global DNA methylation showed a
positive correlation with the expression levels of DNMT1
in the group of HIV controllers (Fig. 4c).
Discussion
Several studies performed in vitro have analyzed how
HIV-1 influences cellular epigenetic mechanisms [22, 23].
Viral infection alters the expression of cellular genes that
modify chromatin structure and affect the process of in-
fection. In addition, the viral genome itself is modified by
some of these mechanisms, which regulate its level of
transcription [8].
Here, we investigated in vivo how the expression of genes
that regulate the chromatin environment is modulated in
CD4+ T cells depending on the viral control and the degree
of progression of patients with HIV.
Overall, the individuals with HIV-1 in our study showed
upregulation in all analyzed chromatin-modifying genes
compared with the non-HIV infected individuals, with
the exception of the PRMT6 gene, which showed down-
regulation. PRMT6 is able to methylate host proteins
such as histone 3, as well as the Tat, Rev, and nucleocap-
sid viral proteins. This interaction with viral proteins
restricts HIV-1 replication [27]. For example, PRMT6 is
able to bind HIV-1 Rev, decrease its stability, and attenu-
ate the Rev-Rev response element-dependent export of
viral transcripts to cytoplasm, thus negatively affecting
HIV replication [28]. Likewise, Tat methylation by
PRMT6 decreases viral transcription [14]. Thus, the virus
might modulate PRMT6 expression to fine-tune its cycle
for its own benefit. An in vitro study mimicking acute
HIV-1 infection found PRMT6 to be downregulated im-
mediately after infection, and its expression further de-
creased over time [22]. Also, knockdown experiments of
PRMT6 showed an increase in viral production and faster
replication [29]. The lower PRMT6 expression found in
our patients with HIV-1 is in accordance with these ob-
servations in vitro and might favor viral replication.
Otherwise, the expression of PRMT6 has been found to
increase in young cells but to decline in replicative and
stressed-induced senescence cells [30], suggesting a regu-
latory role in cell proliferation and senescence. The low
PRMT6 expression in patients with HIV might also sig-
nify CD4+ T cell exhaustion due to a permanent state of
activation, even under antiretroviral treatment. In this
a b
Fig. 2 Expression of mRNA levels of SETDB1, DNMT3a, and HDAC1 in patients positive for HIV. a Correlation between pairs (SETDB1-DNMT3a, SETDB1-
HDAC1, and DNMT3a-HDAC1); (b) Differences in SETDB1, DNMT3a, and HDAC1 expression observed in each group of patients positive for HIV. Y-exe
values represent relative levels of mRNA obtained by the ΔΔCt method. Horizontal bars indicate median values; p values indicate differences for each
gene between noncontrollers versus cART recipients and controllers versus cART recipients
Table 3 Frequency of individuals showing upregulation in all
three genes forming the SETDB1-DNMT3a-HDAC1 complex,
which interacts with Tat
Type of patient SEDTB1 + DNMT3A +
HDAC1 complex
Upregulated p value
HIV negative
(n = 32)
5 (16%) < 0.001
HIV positive
Noncontroller
(n = 26)
8 (31%)
cART recipient
(n = 25)
19 (76%)
HIV-controller
(n = 34)
11(32%)
Due to missing values, only patients with expression values for SEDTB1,
DNMT3A, and HDAC1 were included in this analysis (n = 117). P value indicates
differences between the cART recipients compared to the other subgroups
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regard, the HIV-controllers’ group behaved similarly to
noncontrollers, whereas the cART recipients exhibited a
slightly higher expression of PRMT6 compared with the
other two groups, but still lower than the expression ob-
served in non-HIV infected individuals; this result might
indicate residual levels of cell activation despite the suc-
cess of therapy.
Among the upregulated genes, we can highlight the
SETDB1 gene, which not only showed higher expression in
individuals with HIV-1, but which also had a positive cor-
relation with DNMT3A and HDAC1 expression. The
SETDB1 protein is a histone H3 methyltranferase that, in
the context of HIV-1 infection, interacts with and also
methylates Tat [13], and its knockdown in vitro produces
b c
a
Fig. 3 Western blot analysis. a Cropped gels/blots obtained by each protein evaluation. b, c Quantification of the expression of tested proteins
and differences between HIV and non-HIV infected individuals: b DNMT3a and c DNMT1. The optical density of each sample was measured and
normalized using an Actin run on the same gel. The data are expressed as relative expression (ratio DNMT/actin). Horizontal bars indicate median
values, boxes indicate interquartile range (IQR), and p values for each protein are indicated
a b c
Fig. 4 CpG methylation analysis. a Percentage of 5′-methylcytosine content in genomic DNA in patients with HIV versus non-HIV infected individuals.
Horizontal bars represent mean values and boxes IQR; (b) correlation plot between global DNA methylation and CD4+/CD8+ T cell ratio (Pearson
correlation test); and (c) correlation plot between global DNA methylation and DNMT1 expression in the group of HIV-1 controllers (due to the nature
of variables, the nonparametric Spearman correlation test was used)
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an increase in viral transactivation. At the same time,
SETDB1 has been shown to associate with DNMT3A to
promote gene silencing and also with HDAC1, promoting
closed conformation of chromatin [31, 32]. It has been pro-
posed that methylation of Tat by SETDB1 facilitates viral si-
lencing by recruiting several gene silencing proteins to
remodel chromatin. In our study, we observed that the
cART recipients showed higher upregulation of SETDB1,
and in most of these patients, this increase in expression
was combined with the upregulation of the DNMT3A and
HDAC1 genes. This effect was not observed in the other
two groups of study patients. Moreover, the group of HIV-
controllers behaved similarly to the noncontrollers group.
This observation might suggest the recruitment of repres-
sion machinery toward the HIV-LTR promoter during anti-
retroviral treatment, ultimately increasing viral silencing
and favoring the establishment of a latent reservoir. It
would be interesting to quantify the latent viruses in the
cART recipients and compare them with the group of HIV
controllers. In addition, the poor performance observed in
HIV-controllers regarding SETDB1-DNMT3A-HDAC1,
despite viral control, and their closer phenotype to noncon-
trollers advocates for the beneficial effect of therapy and its
extended use for all patients with HIV-1.
SIRT1 is another gene that associates with Tat and that
showed differences between the cART recipients and the
other two groups of patients with HIV-1. At later phases
of infection, Tat inhibition of SIRT1 appears to be crit-
ical for inducing cell transformation and apoptosis [33].
The cART recipients, due to the effective therapy, might
have lower concentrations of Tat, which in combination
with higher expression of SIRT1, could preserve cells
and attenuate the effect of Tat in disease progression.
We also analyzed the impact of HIV-1 infection on global
DNA methylation. All three groups of patients who were
HIV-1 positive had more methylated DNA than the non-
HIV infected individuals. An increase in DNA methylation
had been observed in vitro within a few hours of HIV-1 in-
fection [23] and in vivo [34]. Likewise, acute HIV infection
alters DNA methyltransferase mRNA expression and DNA
methyltransferase activity, resulting in an increase in gen-
omic methylation in primary cells [35]; Tat itself has been
found to induce overexpression of all three DNMTs [36].
Several studies have linked this increase in methylation to
the upregulation and induction in promoter activity of
DNMT1 [15, 37]. In our patients, there is an increase in
DNMT3A/3B expression, which are the DNA methyltrans-
ferases responsible for de novo DNA methylation. However,
the observed gains in global DNA methylation show a better
correlation with the expression of DNMT1, especially within
the HIV-controller’s group, which concurs with the early
studies mentioned above and with a previous study pub-
lished by our group [17], in which we observed an increase
in methylation in the LTR region in controllers over time.
DNMT1 is usually referred to as the maintenance DNA
methyltransferase, but it also exhibits significant de novo ac-
tivity [38]. In a recent study, Trejbalová and colleagues pos-
tulated that transitory activation of T cells contributes to the
accumulation of DNA methylation in the viral promoter
and that DNMT1 was the enzyme responsible for this [39].
In our HIV-1 controllers, the increase in LTR methylation
over time, the correlation of global DNA methylation, and
DNMT1 expression would support this hypothesis.
Global DNA methylation also alters cellular function.
The changes observed in the methylome of the CD4+ T
cells in infected patients also suggest that HIV-1 mediates
transcriptional repression affecting cell reorganization. In a
recent study, the changes in methylation and increases in
methylome variation observed in CD4+ and CD8+ T cells
occur in aging T cells and affect the expression levels of
genes associated with T cell-mediated immune response,
resulting in impaired T cell function [40]. The global DNA
methylation observed in our patients with HIV-1 as well as
its negative correlation with the CD4+/CD8+ T cell ratio
might resemble what is found in an aging immune system.
We would like to acknowledge some limitations in our
study. First, the number of analyzed patients in HIV sub-
groups is small, and it would be of great interest to repli-
cate these findings in more individuals and other HIV
populations. Second, global DNA methylation has been
measured using an ELISA-based method which serves to
identify large differences in DNA methylation. In our
study differences between HIV and non-HIV infected in-
dividuals were significant; however, other more sensitive
methods should be used to detect smaller differences
within the HIV subgroups. Finally, due to sample limita-
tion, it was not possible to measure the level of each
protein by Western blot to correlate them with mRNA
expression in all studied subjects.
Conclusions
Our study shows alterations in epigenetic mechanisms
due to HIV-1 infection in patients with various degrees
of progression and viral control. There is an increase in
chromatin-modifying enzymes and remodelers, as well
as an increase in global DNA methylation. The group of
treated patients with controlled viremia differs substan-
tially from the other two groups, which show a similar
behavior between them. The fact that patients who have
controlled viral replication without treatment show pro-
files similar to noncontrollers and quite different from
cART recipients supports the benefit of therapy.
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